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Abstract
Background: Health care reform is changing preventive services delivery. This study explored trajectories in colorectal
cancer (CRC) testing over a 5-year period that included implementation of 16 Medicaid Accountable Care Organizations
(ACOs, 2012) and Medicaid expansion (2014) – two provisions of the Affordable Care Act (ACA) - within the state of
Oregon, USA.
Methods: Retrospective analysis of Oregon’s Medicaid claims for enrollee’s eligible for CRC screening (50–64 years)
spanning January 2010 through December 2014. Our analysis was conducted and refined April 2016 through June 2018.
The analysis assessed the annual probability of patients receiving CRC testing and the modality used (e.g., colonoscopy,
fecal testing) relative to a baseline year (2010). We hypothesized that CRC testing would increase following Medicaid ACO
formation – called Coordinated Care Organizations (CCOs).
Results: A total of 132,424 unique Medicaid enrollees (representing 255,192 person-years) met inclusion criteria over the
5-year study. Controlling for demographic and regional factors, the predicted probability of CRC testing was significantly
higher in 2014 (+ 1.4 percentage points, p < 0.001) compared to the 2010 baseline but not in 2012 or 2013. Increased
fecal testing using Fecal Occult Blood Tests (FOBT) or Fecal Immunochemical Tests (FIT) played a prominent role in 2014.
The uptick in statewide fecal testing appears driven primarily by a subset of CCOs.
Conclusions: Observed CRC testing did not immediately increase following the transition to CCOs in 2012. However
increased testing in 2014, may reflect a delay in implementation of interventions to increase CRC screening and/or a
strong desire by newly insured Medicaid CCO members to receive preventive care.
Keywords: Colorectal cancer, Disparities, Medicaid, Accountable care organizations
Background
Colorectal cancer (CRC) is a leading cause of cancer
death in the United States [1, 2]. CRC screening in
asymptomatic, average-risk adults ages 50–75 is recom-
mended by the United States Preventive Services Task
Force (USPSTF) and can be achieved through various
modalities, including colonoscopy every ten years or
using high sensitivity Fecal Occult Blood Tests (FOBT)
or Fecal Immunochemical Tests (FIT) annually [3, 4].
When CRC is detected at an early localized stage, the
five-year survival rate is 90% compared to 13% for can-
cers diagnosed at advanced stages [5]. Yet, only 63% of
age eligible adults in the United States are currently
up-to-date with CRC screening [6]. Disparities in CRC
screening are routinely observed in rural areas and
among adults with limited education, lower incomes, or
Medicaid insurance [1, 7–13].
Improving CRC screening, particularly in populations
experiencing disparities, could reduce CRC incidence
and mortality by up to 60% [3, 14]. Multicomponent
interventions – those using two or more strategies con-
currently - have been shown to improve CRC screening
rates [12, 15, 16]. Yet gaps remain between our knowledge
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of research-tested interventions to improve CRC screen-
ing and their use in routine practice [15, 17]. Moreover,
simulation modeling suggests that substantial investment
(more than $3.75 million) in the implementation of
evidence-based interventions to increase CRC screening
would produce only incremental improvements in overall
CRC screening rates (+ 0.2 to + 0.5 percentage points) in
populations experiencing disparities [18].
Federal and state policies to expand access to
care may improve CRC screening rates. For example, a
central goal of the Affordable Care Act (ACA) was to ex-
pand insurance coverage by establishing Health Insurance
Marketplaces and expanding Medicaid coverage for most
low-income adults with household incomes up to 138% of
the federal poverty level [19]. The ACA also required that
private insurance plans cover recommended preventive
services without any patient cost-sharing (e.g., copay-
ments, deductibles, or co-insurance) [20, 21] and encour-
aged implementation of Accountable Care Organizations
(ACOs) designed to achieve the triple aim objectives of
better population health and quality of care while control-
ling costs [22, 23].
ACOs began in Medicare as a way to deliver high-quality,
coordinated care and provide financial incentives to enhance
accountability [24]. Several states are also experimenting
with ACO structures within their Medicaid programs [25].
Since ACOs are paid a set amount for each patient enrolled,
ACO implementation is anticipated to lead to improved
coordination, wiser spending, and improved quality of care
by delivering the right care to the right patient at the right
time. One quality indicator across many ACO initiatives is
CRC screening [26, 27]. However, the interventions that
ACOs pursue and how they implement them may vary
drastically and have implications on program effectiveness.
To date, limited research describes how transitions from
fee-for-service to ACO structures impacts the completion of
CRC testing or the modalities used among adults with Me-
dicaid coverage.
Therefore, we undertook this study to examine changes in
CRC testing over a 5-year period that includes implementa-
tion of 16 regional ACOs, called Coordinated Care Organi-
zations (CCOs), in a state Medicaid program (Oregon). The
objectives of this study were to: (1) analyze the annual
change in the probability of patients receiving CRC testing
overall and by modality used (i.e., colonoscopy, sigmoidos-
copy, fecal test) relative to a baseline year (2010) and (2)
explore CCO-level modality patterns in CRC testing over
time. We hypothesized that CRC testing would increase
annually following CCO formation.
Methods
Our retrospective analysis explored changes in CRC testing
during a 5-year period that included the transition of
Medicaid enrollees into CCOs (2012–2013) and the
implementation of Medicaid expansion (2014). Our analysis
was conducted and refined April 2016 through June 2018.
The study was approved by the Oregon Health & Science
University Institutional Review Board with a waiver of in-
formed consent (IRB #8865).
Setting
Oregon is noted for its experimentation with Medicaid
enrollment policies [28, 29]. In 2012, Oregon initiated as-
signment of Oregon Health Plan Members (the state’s
Medicaid Program) into 16 regionally-based CCOs. CCO
characteristics are described in detail elsewhere and sum-
marized here [30–33]. CCOs are similar to ACOs in that
they are responsible for providing coordinated health care
services to patients in their region while controlling costs
[34]. CCOs provide coverage for than 90% of Oregon’s
Medicaid population; those not enrolled in a CCO receive
care through the state’s Medicaid fee-for-service program
for reasons related to special health needs (e.g., medically
fragile children). Each CCO is governed locally by a board
consisting of healthcare providers, community members,
and other stakeholders. CCOs operate within a set budget
based on the number of enrollees, with fixed annual
percentage increases in funding [30]. As detailed in
Additional file 1, Oregon’s CCOs vary by geographic region,
size (range: 11,347 to 228,263 enrollees) and racial/ethnic
composition (range: 6.2 to 33.3% Hispanic). CCOs include
both non-profit (n = 9) and for-profit (n = 7) entities.
CCOs are accountable to the state through the track-
ing of multiple quality incentive measures that encom-
pass domains ranging from preventive care to outpatient
and emergency department utilization [35]. CCOs that
meet improvement targets or benchmarks are eligible
for annual performance bonuses from the state [30].
CRC screening has been an incentive measure since the
first year of the CCO program, with reporting initiated
in 2013 [35, 36].
Data collection and analysis
Data source
Administrative claims and enrollment data for Medicaid
enrollees were obtained from Oregon’s Health Systems
Division for a five-year period from January 1, 2010
through December 31, 2014. Claims data include all
healthcare encounters that generated a billing claim for
enrolled members over the study period. Claims data
have been widely used to understand cancer screening
patterns in diverse insured populations [9, 37].
Identification of eligible patients
We applied the same inclusion and exclusion criteria for
each calendar year to generate the analytic sample of eli-
gible Medicaid members: aged 50 to 64 years, not dually
insured by Medicare, had a valid zip code, alive for the
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entire study period, and continuously enrolled in a CCO
(defined as enrolled for at least 11 of 12 months). We
excluded individuals enrolled in Medicare since we did
not have access to Medicare claims data. Consistent with
prior analyses, we also excluded enrollees that had re-
sided in more than two counties during the entire study
period [13] and those with end-stage renal disease, a
terminal illness that would preclude clinicians from
recommending cancer screening [9, 38]. We excluded
beneficiaries with a history of CRC or total colectomy to
better ensure testing eligibility [9]. A total of 132,424
unique Medicaid enrollees met inclusion criteria over
the study period (see Additional file 2).
Primary outcome measures: CRC testing and modality used
We assessed CRC testing by colonoscopy, flexible sig-
moidoscopy, or FOBT/FIT to be consistent with USPSTF
guidelines active during the study window [3, 39]. In the
rare event of multiple CRC testing modalities billed on the
same day of service, we recorded modality based on the
most invasive test received (i.e., colonoscopy > flexible sig-
moidoscopy > FOBT/FIT). CRC testing was identified by
International Classification of Diseases, 9th Edition,
Clinical Modification (ICD-9-CM), Current Procedural
Terminology (CPT), or Healthcare Common Procedure
Coding System (HCPCS) codes, which are summarized in
Additional file 3. For FIT/FOBT, we examined non-spe-
cific codes (i.e., 82,271, 82,272, 82,273) to explore how
often they occurred concurrently with a CRC screening
test-specific code and discovered that usage of non-spe-
cific codes decreased in a stepped fashion from 27.5% in
2010 to 11.0% in 2014. Because this decrement may be re-
lated to coding improvement and not differences in test-
ing behaviors, we kept non-specific procedures in the
analysis. We included both screening and diagnostic bill-
ing codes for colonoscopy in our analysis, consistent with
prior studies [9, 40].
Statistical analysis
First, we used descriptive analyses to determine the
number of eligible Medicaid enrollees, their demo-
graphic characteristics, and the observed rates of CRC
testing annually.
We used multivariate linear regression at the patient-
level to determine the probability of CRC testing for
each calendar year with reference to the baseline year
(2010). Our models controlled for patient-level characteris-
tics including age, gender, race/ethnicity (White, African-
American, Hispanic, Asian/Pacific Islander, American
Indian/Alaska Native, other/unknown), urbanicity (urban,
rural/frontier), chronic disease risk, and use of primary care
within the calendar year. We categorized urbanicity
using the ZIP-code version of the Rural-Urban Com-
muting Areas (RUCA) taxonomy based on population
density, urbanization, and daily commuting patterns:
urban (50,000 or more) versus rural (2500-49,999)
and frontier (< 2500) [41]. We computed Chronic Ill-
ness Disease Payment System (CDPS) indicators from
claims data to adjust for chronic disease risk [42].
Use of primary care within the calendar year was de-
termined from claims based on date of service and a
standard set of CPT codes [43]. CCO fixed effects
controlled for possible clustering of CRC testing out-
comes at the CCO level, and calendar quarter indica-
tors controlled for seasonality.
In addition to regressing on overall CRC testing, we also
fit similar modality-specific models - i.e., where the outcome
is colonoscopy, flexible sigmoidoscopy, or fecal testing. We
also evaluated our selection of a linear probability model
over logistic regression, a common alternative approach for
binary outcome variables. Predicted probabilities of CRC
testing using the linear model were found to be highly corre-
lated with predicted probabilities from a logistic regression
(Pearson’s correlation coefficient 0.961, p < 0.001). When
concordance between approaches is high, the linear model
has the advantage of more intuitive interpretation of the co-
efficients of the independent variables as marginal effects.
Finally, we descriptively examined the annual percentage
of enrollees in each CCO who received CRC testing overall
and by modality. All statistical analyses were conducted in R
version 3.2.2. To protect confidentially, we de-identified
CCOs when reporting data that was not publically available.
Results
A total of 132,424 unique Medicaid enrollees met eligibility
criteria, representing 236,322 person-years over the 5-year
study window. The number of enrollees that met eligibility
criteria varied by study year, from a low of 20,233 in 2010 to
a high of 114,681 in 2014 (following Medicaid expansion in
Oregon). As summarized in Tables 1, 55.4% of eligible enrol-
lees were female; mean age was 56.3 years old. Over half
(56.1%) of these enrollees resided in urban geographic areas.
The majority of Medicaid enrollees visited a primary care
provider during a calendar year (78.6%) and had evidence of
one or more health comorbidities based on medical claims
data (77.3%). Compared to the prior year, the number of eli-
gible patients increased in 2011 (12,121; 60%) and 2014
(79,804; 229%). These increases were concurrent with
state-level changes in Medicaid eligibility criteria. In 2014,
the observed composition of CRC testing modalities in eli-
gible enrollees was 55.8% colonoscopy, 43.4% FOBT/FIT,
and 0.8% flexible sigmoidoscopy.
Marginal changes in probability of CRC testing overall
and by modality
Controlling for demographic and regional factors, the
probability of any CRC testing in eligible enrollees was
significantly higher than the baseline year (2010) in 2011
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(0.7 percentage points, p < 0.001) and 2014 (1.4 percen-
tage points, p < 0.001), see Table 2. While colonoscopy
contributed to the increase in both 2011 and 2014 (0.5
and 0.6 percentage points, respectively), FOBT/FIT also
contributed: 0.2 percentage point increase in 2011 and
0.7 percentage point increase in 2014.
Observed levels of CRC testing and modality patterns by CCO
Observed levels of CRC testing statewide and by CCO
are presented in Additional file 4. Statewide, the ob-
served level of annual CRC testing was 3.2 percentage
points higher in 2014 compared to 2010 (16.2% versus
13.0%). By individual CCO, the relative difference for
any evidence of annual CRC testing in 2014 compared
to 2010 ranged from a decrease of 0.5 percentage points
(− 0.5, CCO N) to an increase of 9.8 percentage points
(+ 9.8, CCO E).
CRC testing modality patterns varied within and
across CCOs over time. Figure 1 illustrates trajectories
for CRC testing annually overall and by modality type
for each CCO. Use of flexible sigmoidoscopy was rare
across all CCOs. Some CCOs displayed a relatively high
level of CRC testing using FOBT/FIT across all study
years (i.e., CCOs A - E), whereas others demonstrated a
relatively low level of FOBT/FIT use (i.e., CCOs I – P).
Two CCOs (F and G) displayed distinct upticks in CRC
testing using FOBT/FIT following formation of CCOs in
2012. Many CCOs displayed a spike in CRC testing in
2011, driven by colonoscopy usage, and a few CCOs
displayed an uptick in overall CRC testing in 2014 that
appeared to be driven by colonoscopy (i.e., CCOs 0 and
P) or by a combination of colonoscopy and FOBT/FIT
(i.e., CCOs D - J).
Discussion
This study explored changes in CRC testing and the modal-
ity used among Medicaid enrollees in Oregon over a
five-year period that included implementation of numerous
ACA provisions, such as the transition of Medicaid mem-
bers into 16 ACOs (CCOs, 2012) and Medicaid expansion
(2014). Compared to the baseline year (2010) the probabil-
ity of CRC testing statewide significantly increased in 2011
and 2014 by 0.7 and 1.4 percentage points, respectively.
Modality of CRC testing varied by CCO over time related
to consistently high or low use of FIT/FOBT or an uptick
in FIT/FOBT following CCO formation.
This increase in annual CRC testing in 2011 and 2014
statewide may be driven in part by the increased number
of eligible enrollees in both years (12,121 or 60% in 2011;
79,804 or 229% in 2014) – which corresponds with
changes in state-level eligibility requirements for Medicaid
enrollment. This adds to the robust body of research that
demonstrates that insurance coverage is an important
predictor of preventive screening [28, 29]. However, it is
notable that the modality driving these CRC testing up-
ticks varied. While colonoscopy drove the 2011 uptick,
FOBT/FIT played a prominent role in the 2014 increase.
Table 1 Demographics of Eligible Oregon Medicaid Enrollees,
2010–2014
Characteristic Overall N = 236,322
Gender
Female 55.4
Male 44.6
Age (average) 56.3
Race/Ethnicity
White 73.1
African-American 3.7
Hispanic 8.4
Asian/Pacific Islander 3.4
American Indian/Alaskan Native 1.9
Other/Unknown 9.5
PCP visit during 2014 78.6
PCP visit during calendar year 82.1
Geographic area
Urban 56.1
Rural/Frontier 43.9
Health comorbiditiesa 77.3
aHealth comorbidities identified using Chronic Disease and Disability Payment
System (CDPS) risk indicators
Table 2 Marginal Annual Effects of Colorectal Cancer Testing Overall and by Modality in 16 Medicaid ACOs, 2011–2014 Compared
to 2010, percentage point (p-value)
CRC Screening Modality
Year effect relative to 2010 Any CRC screening Colonoscopy FOBT/FIT Flexible sigmoidoscopy
2011 0.007 (< 0.001) 0.005 (< 0.001) 0.002 (< 0.001) < 0.001 (< 0.001)
2012 0.001 (0.333) 0.001 (0.022) 0.000 (0.691) < 0.001 (< 0.001)
2013 0.001 (0.104) −0.001 (0.186) 0.002 (< 0.001) −0.001 (< 0.001)
2014 0.014 (< 0.001) 0.006 (< 0.001) 0.007 (< 0.001) < 0.001 (< 0.001)
Note: Each column represents a separate regression model. These coefficients represent the annual marginal change in the predicted probability of the outcome
relative to the baseline year (2010). Each model also controls for age, gender, race/ethnicity, chronic disease risk, urbanicity, PCP visit during the calendar year,
CCO assignment, and calendar quarter. Results are interpreted as percentage point changes compared to a 2010 baseline
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The uptick in 2014 may be related to the formation of
CCOs and the subsequent interventions they imple-
mented to increase CRC testing – one CCO quality incen-
tive metric. Variation in modality patterns within
individual CCOs suggests that these health plans may
implement different interventions or implement the same
interventions in more or less effective ways [44].
The ACA has encouraged rapid transformation of health
systems with the triple of aim of improving care quality and
patient outcomes while controlling costs [22]. Evidence de-
scribing how ACO payment structures impact utilization of
preventive services and clinical outcomes in Medicaid pa-
tients is still emerging [32]. This is the first study, to our
knowledge, to examine changes in CRC testing in a context
that includes formation of Medicaid ACOs and implemen-
tation of other ACA provisions. Although ACOs originated
in Medicare, by 2018 12 states had implemented some
form of ACO program within Medicaid, and 10 more were
pursing them [25]. The effectiveness of ACO structures on
preventive care delivery, which includes CRC screening, ap-
pears dependent on organization characteristics [45–47].
Building relationships, providing actionable data, and
supporting quality improvement infrastructure are critical
dimensions when CCOs work with primary care clinics to
implement interventions to increase CRC screening [44].
Uncertainty about the future of the ACA underscores the
need for research like ours to understand how such health
reforms affect patients’ receipt of preventive services, such
as CRC screening.
Policies provide standards and guidance for ACOs,
health systems, and individual primary care practices.
However, decisions on what and how to implement inter-
ventions to achieve policy targets are often determined
based on local context and stakeholder priorities. Inter-
ventions to increase CRC screening and address cancer
disparities may benefit by focusing on local contexts as
the starting point to inform intervention selection, align-
ment, and implementation [17, 48, 49]. Research exploring
how to help ACOs select and implement interventions
that are evidence based and best suited to their specific
patient populations, clinical settings, and community
characteristics [15] by modeling intervention impact [18]
or using participatory implementation science methods
[49] is needed. Future studies could also explore how the
interventions implemented within ACOs interact with
patient-level characteristics to explain variation in moda-
lity of CRC testing over time. For example, additional re-
search is needed to determine if patients that are newly
insured following Medicaid expansion are highly receptive
to completing preventive screenings such as CRC testing
in order to “catch up” on their health care.
Although the percentage of individuals who are
up-to-date with CRC screening is improving nationally,
further movement is needed to achieve the National
Colorectal Cancer Roundtable (NCCRT) target of 80%
and to address disparities in vulnerable populations (e.g.,
minorities, Medicaid enrollees, rural patients) [1, 7, 12,
50–52]. Many evidence-based interventions increase
CRC screening and a number of federally sponsored ini-
tiatives such NCI’s Cancer Moonshot and the Cancer
Prevention and Control Research Network (CPCRN)
[53] are designed to speed translation of this evidence
Fig. 1 Annual Observed CRC Testing Trajectories and Modality Used in Eligible Enrollees in 16 Medicaid ACOs, 2010–2014
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into routine practice. Achieving national targets for CRC
screening would prevent 277,000 new cases of colon
cancer and 203,000 deaths within 20 years [54]. Under-
standing how policies and interventions are being effect-
ively implemented within states and individual Medicaid
ACOs may contribute to increased CRC screening and
ultimately help eliminate observed disparities.
Our study has several limitations. First, we relied on
administrative claims to quantify the percentage of eli-
gible enrollees that were tested for CRC in any calendar
year rather than the proportion of enrollees who were
up-to-date. We chose this approach because we lacked
access to claims data needed to monitor colonoscopy
completion. This approach likely yields a greater fre-
quency of FOBT/FIT testing compared to colonoscopy
because of the disparate recommended screening win-
dows (annually versus every 10 years). Second, we were
unable to compare changes in CRC screening in our
Medicaid population to a control group because most of
the state’s Medicaid population was enrolled in CCOs
and only a small, remarkably dissimilar population
remained in fee for service. Our findings over time, and
within CCOs, suggest that research comparing observed
changes in CRC testing in ACO programs and sites not
implementing ACO structures is warranted. Finally,
since we focused on Medicaid ACOs in Oregon, it is un-
known if observed patterns would appear during ACO
implementation among non-Medicaid populations (e.g.,
commercially insured, uninsured) or in different geo-
graphic regions. Despite these limitations, our study pro-
vides preliminary data to shape future research on the
impact of ACA provisions and ACO implementation on
CRC screening and may apply to other preventive
services.
Conclusion
Our study suggests that ACO formation and Medicaid
expansion – two provisions of the ACA – are associated
with increased CRC testing. Compared to the 2010 base-
line, the probability of CRC testing in Medicaid enrollees
increased by 1.4 percentage points in 2014. This delay in
increased CRC testing following the transition to CCOs
in 2012, may reflect the time required for implementa-
tion of interventions to increase CRC screening and/or a
strong desire by newly insured Medicaid CCO members
to receive preventive care. While we observed that in-
creased CRC testing was associated with years in which
there was a greater number of Medicaid enrollees (2011,
2014) – it is notable that the 2014 increase was also
driven by an increase in the use of FIT/FOBT compared
to prior years. These findings suggest that formation of
CCOs, with an incentive metric related to CRC screen-
ing, contributed to increased CRC testing driven in part
by greater use of FIT/FOBT. Given that simulation
modeling suggests that investments of $3.75 million to
support implementation of evidence-based interventions
would yield only incremental improvements in CRC
testing (+ 0.2 to + 0.5 percentage points) in underserved
populations [18]; the observed 1.4 percentage point in-
crease in 2014 appears to be substantial. Further study
of the relationships between the interventions used, im-
plementation strategies, and improvements in testing
across the CCOs, and in other ACO and non-ACO
settings, is warranted.
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Additional file 1: Characteristics of Oregon’s 16 Coordinated Care
Organizations (CCOs), 2014 Public Data. This table provides a snapshot of
Oregon’s 16 CCOs by organizational structure, nonprofit status, location,
size (number of enrollees) and the percent of eligible Medicaid members
who were up-to-date for CRC screening based on 2014 public data.
(DOCX 14 kb)
Additional File 2: Inclusion and exclusion criteria applied to generate
analytic sample for Medicaid members. This table summarizes where
individuals “fell out” of the analytic sample as we applied our inclusion
and exclusion criteria. The lines in the table parallel the descriptors that
are presented in the manuscript text. (DOCX 12 kb)
Additional File 3: Billing codes indicating colorectal cancer screening
procedures or exclusion criteria. This table presents all of the CPT, HCPCS,
and ICD-9 Procedure codes that we applied to our claims data in order
to assess the primary outcome of CRC testing and modality used. We
present our codes for screening test modality and exclusion reason. This
information is provided to support transparency and help others who are
doing this work. Because our analysis was on data collected prior to
2014, we did not present ICD-10 Procedure codes in this table but is
available from the authors upon request. (DOCX 13 kb)
Additional File 4: Observed Levels of Any Colorectal Cancer Testing
State-wide and by Medicaid ACO, 2010 to 2014. This table summarizes
observed levels of CRC testing across all five study years by individual
CCO, and across the state. This information complements the data pre-
sented in Fig. 1 and is provided in case readers would like to see the ac-
tual numeric value displayed for individual CCOs. (DOCX 13 kb)
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